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Using in vivo-induced antigen technology (IVIAT), a modified immunoscreening technique that circumvents
the need for animal models, we directly identified immunogenic Escherichia coli O157:H7 (O157) proteins
expressed either specifically during human infection but not during growth under standard laboratory conditions or at significantly higher levels in vivo than in vitro. IVIAT identified 223 O157 proteins expressed
during human infection, several of which were unique to this study. These in vivo-induced (ivi) proteins,
encoded by ivi genes, mapped to the backbone, O islands (OIs), and pO157. Lack of in vitro expression of
O157-specific ivi proteins was confirmed by proteomic analysis of a mid-exponential-phase culture of E. coli
O157 grown in LB broth. Because ivi proteins are expressed in response to specific cues during infection and
might help pathogens adapt to and counter hostile in vivo environments, those identified in this study are
potential targets for drug and vaccine development. Also, such proteins may be exploited as markers of O157
infection in stool specimens.
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157)
is a uniquely human pathogen that causes disease ranging from
acute, self-resolving watery diarrhea to hemorrhagic colitis and
the potentially fatal hemolytic-uremic syndrome (HUS). Currently, no therapies are available to lessen the potential morbidity and mortality of this infection.
E. coli O157 is thought to have evolved from a strain of
enteropathogenic E. coli (EPEC) O55:H7 bearing the pathogenicity island termed the locus for enterocyte effacement
(LEE), through the acquisition of bacteriophages encoding
Shiga toxins type 1 (stx1) and/or 2 (stx2), acquisition of a virulence plasmid (pO157), transition of somatic antigen O55 to
O157, and loss of sorbitol fermentation and ␤-glucuronidase
activity (21). HUS as a complication of E. coli O157 infection
has been associated with the presence of the stx2 gene or its
variant stx2c in the infecting E. coli O157 strain (21). In addition, the characteristic attaching and effacing (A/E) lesions
produced by this organism on the human colonic epithelium
are a result of proteins encoded on the LEE, including the
adhesion molecule intimin-␥ (Eae), its receptor (Tir), the type
III protein secretion system, which secretes a variety of LEEencoded translocator proteins (EspA, EspB, and EspD) that

translocate effectors into host cells, and effector proteins (Tir,
EspG, EspF, Map, and EspH) that modulate the host cell
cytoskeleton (21). The type III secretion system translocates
Tir into the host cell, with subsequent trafficking to the host
cell membrane. Intimin binding of Tir leads to host cell actin
rearrangement and formation of A/E lesions. Other putative
virulence factors are encoded on pO157 and include an enterohemolysin (Ehx), an immunomodulator (Lif), and a serine
protease (EspP) (21). Hence several factors may be involved in
E. coli O157 pathogenesis, and research is ongoing to understand the complexity of this infection.
The sequenced E. coli O157 EDL933 genome shows that
although this organism shares 4.1 Mb of DNA (termed backbone) with E. coli K-12, it has 1.34 Mb of DNA distributed
among 177 DNA segments termed O islands (OIs) that is
absent in K-12 (44). Of the genes found in these OIs, only 40%
have been assigned a function and several remain to be characterized (44). Collective evidence indicates that intimin-␥
and the Shiga toxins act in concert with other, unidentified
virulence factors, encoded by both the OI and backbone sequences, to cause the spectrum of E. coli O157 disease (21, 54).
To date, the main impediment to identifying a broader complement of virulence factors in this pathogen has been the lack
of an animal model that mimics the spectrum of human disease. Also, the potentially fatal sequelae that can follow E. coli
O157 infection preclude human volunteer studies. We circumvented these limitations and exploited the human immune
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MATERIALS AND METHODS
Recombinant DNA methods. Isolation of plasmid DNA, restriction digestions,
and agarose gel electrophoresis were performed using standard procedures (48).
All enzymes for restriction digestions, DNA modifications, and ligations were
from New England Biolabs, Beverly, MA. DNA sequencing was performed at the
DNA Sequencing Core Facility, Department of Molecular Biology, Massachusetts General Hospital, using ABI Prism DiTerminator cycle sequencing with
AmpliTaq DNA polymerase FS and an ABI 377 DNA sequencer (Perkin-Elmer
Applied Biosystems Division, Foster City, CA). Oligonucleotides for PCR and
sequencing were obtained from the DNA Synthesis Core Facility, Department of
Molecular Biology, Massachusetts General Hospital. Plasmids were electroporated into E. coli DH5␣ or BL21(DE3) using a Gene Pulser (Bio-Rad Laboratories, Richmond, CA) as instructed by the manufacturer. Electroporation conditions were 2,500 V at 25-mF capacitance, producing time constants of 4.8 to
4.9 ms.
Bacterial strains, plasmids, and growth conditions. An isolate of E. coli O157,
from a patient who recovered from recent, clinically diagnosed HUS and contributed a serum sample to the pool of convalescent-phase sera for probing the
expression library, was used to construct the DNA expression library (see below).
E. coli X21-Blue(pEB313) expressed an intracellular derivative of intimin-␥,
His6–intimin-␥ (35), from which the putative signal sequence of 34 amino acids
had been removed (a gift of Alison O’Brien, Uniformed Services University of
the Health Sciences, Bethesda, MD.). E. coli DH5␣(pCVD468, pREP4) expressing a genetically engineered version of EspA, His6-EspA (22), was a gift from
James B. Kaper, University of Maryland School of Medicine, Baltimore, MD.
Bacterial strains were grown in vitro in Luria-Bertani (LB) medium and maintained at ⫺70°C in LB broth containing 15% glycerol. Kanamycin (Kan) and
ampicillin (Amp) were used at concentrations of 50 g/ml and 100 g/ml,
respectively.
Patient and control sera. Convalescent-phase sera (approximately 500 l/
patient) were obtained from four patients who had recovered from HUS following E. coli O157 infection. The ages of the patients ranged from 2 to 10 years, and
sera were collected on days 13 to 96 postillness. A serum sample from a healthy
pediatric patient was used as the control. All of the above serum samples were
collected at the Children’s Hospital and Regional Medical Center, Seattle, WA,
for routine laboratory investigations, and only excess sera were used for this
study. The Institutional Review Board of the Children’s Hospital and Regional
Medical Center approved the use of these sera, which were stored at ⫺70°C until
use.
Assessment of reactivities of pooled, unadsorbed HUS convalescent-phase and
healthy control sera with immunogenic O157 proteins. Sera were assessed by
examining their reactivities via colony immunoblotting (described below) against
E. coli XL1-Blue(pEB313), expressing His6–intimin-␥, plated onto LB-Amp
plates (35) and against E. coli DH5␣(pCVD468, pREP4), expressing His6-EspA,
plated onto LB-Amp-Kan plates (22). Both EspA and intimin-␥ are expressed
during human infection and targeted by the immune response (22, 35).
Adsorption of HUS convalescent-phase and control sera. To compensate for
variations in immune responses of individual patients and identify the widest
array of O157 antigens, equal volumes of HUS convalescent-phase serum samples from four patients were pooled and sequentially adsorbed against the E. coli
O157 isolate recovered from one of the four patients (the same E. coli O157
isolate used to generate the expression library).
The adsorption protocol has been described previously (12). Briefly, a protease

inhibitor cocktail formulated for bacterial cells and containing 4-(2-aminoethyl)
benzenesulfonyl fluoride (AEBSF; 23 mM), EDTA (100 mM), bestatin (2 mM),
pepstatin A (0.3 mM), and E-64 (0.3 mM) was prepared per the manufacturer’s
(Sigma, St. Louis, MO) instructions and then added to intact cells and cell lysates
at a dilution of 1:10. Pooled HUS convalescent-phase sera were sequentially
adsorbed against in vitro-grown (LB broth, 37°C) E. coli O157 whole cells, cell
lysates (prepared by three cycles of freezing and thawing, followed by sonication), and heat-denatured cell lysates (12). Adsorbed sera were stored at ⫺70°C
until further use.
Individual HUS convalescent-phase serum samples from each of the four
patients and the control serum sample were adsorbed against whole cells, cell
lysates, and heat-denatured cell lysates of the in vitro-grown (LB-Kan broth,
37°C) expression host, E. coli BL21(DE3) containing the native pET-30abc
expression plasmids, in a similar manner.
The efficiency of adsorption of pooled HUS convalescent-phase sera was
assessed using an enzyme immunoassay described previously (12) and detailed
below. Adsorption efficiency was further evaluated by reacting sera with recombinant clones expressing His6–intimin-␥ and His6-EspA via colony immunoblotting as described below.
Efficiency of adsorption of pooled HUS convalescent-phase sera. Microtiter
wells were coated with 100 l of a 1:2 dilution of a lysate of in vitro-grown E. coli
O157 (the same isolate used to make the DNA expression library) in 50 mM
carbonate buffer (pH 9.6), prepared by three cycles of freezing and thawing
followed by sonication. Following overnight incubation at room temperature,
wells were washed with phosphate buffered saline (PBS) containing 0.05% of
Tween 20 (PBS-T) and blocked with a 1% solution of bovine serum albumin.
After a 1-h incubation at 37°C, wells were emptied, and 100 l dilutions (1:200
to 1:25,600) of sera, removed from the pool after each adsorption step, were
added to wells. The wells were incubated for 1 h at 37°C and washed, after which
100 l of a 1:1,000 dilution of horseradish peroxidase-conjugated goat antihuman affinity-purified immunoglobulin G (IgG), reactive against all classes of
human immunoglobulins (ICN, Cappel, Aurora, OH), was added to the wells.
Wells were incubated for 1 h at 37°C and washed with PBS-T. Reactions were
developed with a 1-mg/ml solution of 2,2⬘-azinobis(ethylbenzthiazolinesulfonic
acid) (ABTS; Sigma, St. Louis, MO) with 0.1% H2O2 (Sigma). The optical
density at 405 nm (OD405) was determined kinetically with a Vmax microplate
reader (Molecular Devices Corporation, Sunnyvale, Calif.). Plates were read for
5 min at 19-s intervals, and the maximum slope for an OD change of 0.2 U was
determined as milli-OD units/min (20).
Construction of an inducible E. coli O157:H7 genomic DNA expression library. Polymorphic amplified typing sequences, a powerful and user-friendly
typing methodology for bacterial pathogens that compares well with pulsed-field
gel electrophoresis (24, 25), profiled the cognate E. coli O157 isolates from the
four HUS patients as heterogeneous. We therefore selected one isolate at random, purified genomic DNA, and generated the DNA expression library.
To generate the expression library, vector DNA was prepared by digesting with
the restriction enzyme BamHI (New England Biolabs, Beverly, MA). The vectors
used were the pET-30abc series of expression vectors (Novagen, Madison, WI),
which permit the cloning of inserts in each of the three reading frames under the
transcriptional control of the T7 phage promoter. The restriction enzyme-digested plasmid DNA was gel purified using the QIAEX II gel extraction kit
(QIAGEN, Valencia, CA) and then treated with shrimp alkaline phosphatase.
Genomic DNA of an E. coli O157 isolate from one of the four HUS patients was
partially digested with the restriction enzyme Sau3AI. Following fractionation on
a 1% agarose gel, DNA fragments ranging from ca. 0.5 to 1.5 kbp (insert DNA)
were excised and purified using the QIAEX gel extraction kit (QIAGEN).
Various ratios of insert and vector DNA were ligated and used to transform
competent E. coli DH5␣ via electroporation according to standard protocols
(48). Transformants were plated onto LB plates supplemented with 50 g/ml of
Kan (LB-Kan). After an overnight incubation at 37°C, growth was scraped off the
plates and plasmid DNA was isolated using standard procedures (48) and used
to transform electrocompetent E. coli BL21(DE3) (Novagen), a general-purpose
expression host. To determine the percentage of transformants containing inserts, the library was plated onto LB-Kan plates, and 100 colonies were randomly
picked and analyzed by colony PCR using vector-specific primers. More than
90% of transformants contained inserts ranging from 0.2 kbp to 1.8 kbp.
Screening of the expression library and identification of clones expressing
immunogenic O157 proteins. The expression library was first screened with
pooled unadsorbed HUS convalescent-phase sera as follows. An optimal dilution
of the library in E. coli BL21(DE3) was plated onto LB-Kan plates to yield ca.
300 to 350 colonies per plate. After 5 h of incubation at 37°C, colonies were lifted
using a nitrocellulose filter and placed, colony side up, on fresh LB-Kan plates
containing 1 mM isopropyl-␤-D-thiogalactoside. Plates were incubated overnight
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response following E. coli O157 infection to identify a panel of
microbial factors that might contribute to the pathogenicity
of this organism. In particular, we used a modified immunoscreening technique called in vivo-induced antigen technology
(IVIAT) (11), which enables identification of antigens expressed specifically during infection but not during growth in
standard laboratory media. The rationale was that such immunogenic O157 antigens, expressed in response to unique signals
encountered within the gastrointestinal tract, might contribute
to pathogen adaptation and survival within the gut and hence
might play important roles in the virulence of this organism.
Here we report the identification of O157 proteins that are
expressed during human infection. We expect the proteins
identified to be potential targets for development of diagnostics, drugs, and vaccines.
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FIG. 1. Reactivities of pooled unadsorbed (A) and adsorbed (B)
HUS sera against two known E. coli O157 virulence proteins, intimin and EspA, and an unrelated negative-control protein, PilA, from
V. cholerae.

the Bioworks Browser 3.1. Sequential database searches were made using the E.
coli O157:H7 strain EDL933 FASTA database from the European Bioinformatics Institute (http://www.ebi.ac.uk/newt/display) of the European Molecular Biology Laboratory using differential carbamidomethyl-modified cysteines and oxidized methionines. A yeast protein database was spiked in to provide noise and
determine the validity of the peptide hits. In this fashion, known and theoretical
protein hits can be found without compromising the statistical relevance of all
the data (43). Peptide score cutoff values were chosen at cross-correlation values
(Xcorr) of 1.8 for singly charged ions, 2.5 for doubly charged ions, and 3.0 for
triply charged ions, along with deltaCN values of 0.1 and cross-correlation normalized values of 1. The Xcorr chosen for each peptide ensured a high confidence match for the different charge states, while the delta rank scoring preliminary cutoff ensured the uniqueness of the peptide hit; the RSP value of 1
ensured that the peptide matched the top hit in the preliminary scoring.

RESULTS AND DISCUSSION
Pooled unadsorbed HUS convalescent-phase sera reacted
specifically with previously identified immunogenic O157 proteins. Pooled unadsorbed HUS convalescent-phase sera reacted strongly and specifically with E. coli XL1-Blue(pEB313)
(35) and E. coli DH5␣(pCVD468, pREP4) (22), expressing
His6–intimin-␥ and His6-EspA, respectively, in contrast to
E. coli BL21(DE3) expressing recombinant Vibrio cholerae
PilA, an irrelevant control protein (Fig. 1A). This suggested
that the pool of sera possessed sufficient reactivity for probing the expression library. On the other hand, the unabsorbed
healthy-control serum did not react with either of these proteins (data not shown).
Adsorption of pooled HUS convalescent-phase sera as per
the IVIAT protocol resulted in selective depletion of antibodies
against O157 antigens expressed in vitro. Adsorption efficiency was determined by examining the reactivities of serum
aliquots from pooled HUS convalescent-phase sera after each
adsorption step with lysates of in vitro-grown E. coli O157.
There was a sharp decline in the reactivities of sera against the
lysates of in vitro-grown E. coli O157 following the first adsorption step compared to those of the unadsorbed sera, indicating efficient depletion of antibodies against in vitro-expressed O157 proteins (Fig. 2).
Although the adsorbed sera continued to react with the
clone expressing His6–intimin-␥, it did not react with the clone
expressing His6-EspA (Fig. 1B). Since both are reportedly expressed during human infection (22, 29), as well as during in
vitro growth (36), we anticipated reactivity with both might be
eliminated by adsorption of the sera. We attribute the residual
serum reactivity with intimin-␥ to relatively weak in vitro expression of this protein, which may be insufficient to adsorb
away all of the anti-intimin-␥ antibodies generated in response
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at 30°C to induce expression of genes contained within cloned inserts. Colonies
on plates were partially lysed by exposing them to chloroform vapors for 15 min
in a candle jar. The filters were removed from the plates, air dried, and blocked
using 5% nonfat milk in PBS (pH 7.4) for 1 h at room temperature. After a rinse
with PBS-T, the filters were probed with a 1:500 dilution of pooled unadsorbed
HUS convalescent-phase sera for 1 h at room temperature on a rocking platform.
Filters were washed three times with PBS-T and incubated with a 1:5,000 dilution
of peroxidase-labeled goat IgG directed against the human gamma globulin
fraction (ICN/Cappel). Following development with an ECL chemiluminescence
kit (Amersham Pharmacia Biotech), reactive clones were identified by their
positions on the reference plate (the original plate from which the colonies were
lifted, which was also incubated overnight at 30°C). Each reactive clone identified
in the primary screen was purified further, picked with a toothpick in a grid
pattern such that each test clone alternated with E. coli BL21(DE3)(pET-30a),
the negative control, and processed as described above.
Identification of O157 proteins expressed during human infection by using
IVIAT. To identify proteins expressed by E. coli O157 during human infection,
the clones identified above were subjected to IVIAT using pooled adsorbed HUS
convalescent-phase sera. Clones were picked with a toothpick onto LB-Kan plates in
a grid pattern and incubated for 5 h at 37°C. Processing of filters and screening
were identical to those described above, except that a 1:100 dilution of pooled
adsorbed HUS convalescent-phase sera was used as a probe. Following confirmation by four additional rounds of screening, plasmid inserts were sequenced
and encoded proteins were identified via BLAST against the genomic sequences
of E. coli O157:H7 strains EDL933 and Sakai. Proteins expressed from inserts
within positive clones were called in vivo-induced proteins (ivi proteins), and the
genes encoding them were referred to as ivi genes. Positive clones were further
probed with individual adsorbed HUS convalescent-phase serum samples from
each of the four patients and the control serum sample, as described above.
Cellular localization of ivi proteins was predicted using the PSORT/PSORT-B
program (http://psort.nibb.ac.jp/). Hypothetical ivi proteins were assigned putative functions using the Clusters of Orthologous Groups (COGs) database,
available at http://www.ncbi.nlm.nih.gov/COG/. The online browser tool Proteome Navigator was used to compare proteins not assigned specific functions by
the COGs database against Prolinks, a database of protein functional linkages
derived from coevolution (2), available at http://dip.doe-mbi.ucla.edu/pronav.
Proteomic analysis of E. coli O157 grown in LB broth using ESILC-MS/MS.
To determine whether ivi proteins were expressed when E. coli O157 was cultured under standard laboratory conditions, E. coli O157 grown in LB broth was
subjected to microcapillary high-performance liquid chromatography combined
with electrospray ionization tandem mass spectrometry (ESILC-MS/MS) at the
Harvard Partners Center for Genetics and Genomics, Cambridge, MA. The E.
coli O157 whole cells for one-dimensional LC-MS/MS analysis were prepared
as follows. Mid-log-phase E. coli O157 (OD600, 0.7), cultured at 37°C in LB
broth, was pelleted via centrifugation at 4°C and washed twice in deionized water.
Cells were aliquoted into 1.5-ml tarred centrifuge tubes, frozen at ⫺80°C, and
lyophilized to dryness under a high vacuum. The tubes were then weighed again
and the total dried cell pellet weight determined. Dried E. coli O157 pellets (2
mg) were dissolved in 200 l of 6 M urea, 1% sodium dodecyl sulfate, 100 mM
ammonium bicarbonate, and 10 mM dithiothreitol (pH 8.5). Samples were vortexed, and following incubation at 37°C for 1 h, 12 l of 500 mM iodoacetamide,
100 mM ammonium bicarbonate (pH 8.5) was added to each 200-l sample. The
reaction was allowed to proceed at room temperature for 1 h in the dark. Alkylation was quenched by the addition of 2 l of 2 M dithiothreitol in 100 mM
ammonium bicarbonate, pH 8.5. Samples were then diluted eightfold with 5 mM
CaCl2, mixed with 20 g of Promega sequencing-grade trypsin, and incubated at
37°C for 16 h. Following quenching with 2 l of formic acid, samples were diluted
with 2 ml of 0.1% formic acid and cleaned up using a Waters Oasis MCX cartridge. Peptides were eluted with 6% ammonium hydroxide in 50% acetonitrile,
frozen, and lyophilized. Samples were redissolved in 5% acetonitrile–0.1% formic
acid/water and loaded onto a 96-well plate for mass spectrometry (MS) analysis.
For MS, samples were run on an LCQ DECA XP plus Proteome X workstation from Thermo Finnigan. For each run, 85 l of reconstituted sample was
injected with a Surveyor Autosampler, while the separation was done on a
250-m (inner diameter) by 30-cm column packed with C18 medium running at
a 2-l-per-minute flow rate provided from a Surveyor MS pump with a flow
splitter, with a gradient of 5 to 72% water, 0.1% formic acid, and 5% acetonitrile
over the course of 240 min (4 h). Two such runs were performed. Between each
set of samples, two standards of a 5 Angio mix of peptides (Michrom BioResources) were run to ascertain column performance and observe any potential
carryover. The LCQ was run in a top five configuration, with one MS scan and
five MS/MS scans. Dynamic exclusion was set to 1, with a limit of 30 seconds.
Peptide identifications were made using SEQUEST (Thermo Finnigan) through
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to significantly higher expression of this adhesin within the
gastrointestinal tract.
Screening of an E. coli O157 genomic expression library.
Primary screening of ca. 50,000 clones of an E. coli O157 genomic expression library, using pooled unadsorbed HUS convalescent-phase sera, yielded 918 reactive clones. IVIAT of
these clones using pooled adsorbed HUS convalescent-phase
sera identified 223 persistently reactive clones containing unique
inserts as determined from nonredundant databases.
ivi proteins included previously identified E. coli O157 virulence-related proteins. IVIAT identified four proteins previously reported to have a putative role in E. coli O157 virulence
(1) (Table 1). (i) Intimin-␥ is a LEE-encoded outer membrane
adhesin that acts in concert with other LEE-encoded proteins
to generate the A/E lesion (21) and to effect binding to host
nucleolin (50) to tether the bacterium to the enterocyte. (ii)
QseA, a backbone-encoded LysR-type quorum-sensing E. coli
transcriptional regulator, is part of the regulatory cascade that
controls expression of O157 virulence factors via quorum sensing (52). QseA is also present in other gastrointestinal pathogens such as EPEC (QseA) and V. cholerae (AphB). Following
activation by the furanone AI-2, QseA activates transcription
of Ler, the positive activator of the LEE operon, and thereby influences expression of putative virulence factors from
the LEE. A qseA mutant is impaired in the secretion of LEEencoded proteins via the type III secretion system, also encoded on the LEE (53). (iii) TagA, a pO157-encoded inner membrane lipoprotein (41), is a protein of unknown function, but a
putative role in E. coli O157 virulence has been suggested
because of its presence in a diverse collection of E. coli O157

TABLE 1. ivi proteins with reported roles in O157 pathogenesis
IVIAT
clone

Insert localization on
EDL933 genome

Gene/protein/functiona

H-310
H-13, -75
H-124
H-314

OI 148
pO157
pO157
Backbone

eae/intimin/attaching and effacing
msbB2/MsbB/lipid A acyltransferase
L7031/probable toxR-regulated lipoprotein TagA
qseA/transcriptional regulator, LysR type;
quorum-sensing E. coli regulator A

a
b
c

No. of reactive serac

Bacterial-cell
localizationb

Contig/plasmid
accession no.

HUS sera

Control serum

Outer membrane
Inner membrane
Inner membrane
Cytoplasm

AE005595
AF074613
AF074613
AE005552

4
4
4
4

0
0
0
0

Putative functions of hypothetical proteins determined from the COGs database when available.
Predicted by the PSORT/PSORT-B program.
Sera from four patients with HUS and one healthy person were tested individually.
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FIG. 2. Enzyme immunoassay reactivities of sera with lysates of in
vitro-grown E. coli O157 after each step in sequential adsorption.
OD405 values were corrected for background and for dilution during
adsorption.

strains (41) and the fact that a homolog in V. cholerae is regulated by ToxR, a transcriptional regulator that governs expression of several V. cholerae virulence factors (13). (iv) MsbB2, a
pO157-encoded inner membrane acyltransferase, facilitates
the synthesis of hexaacyl lipid A, the form with maximal biological activity (23). MsbB2 reportedly functions to suppress
minor modifications of lipid A. Acting in conjunction with
MsbB1, another homologous acyltransferase expressed from
the chromosome, MsbB2 facilitates the synthesis of lipid A of
maximal biological activity, which interacts optimally with the
host immune system to evoke an immune response to LPS
(23). Strongly supporting a role for MsbB2 in E. coli O157
virulence is the fact that LPS reportedly acts synergistically
with the Shiga toxins, especially Stx2, in the pathogenesis of
HUS (19). Further support for a likely role in E. coli O157
virulence is suggested by observations that MsbB2 contributes
to the virulence of related pathogens such as Shigella flexneri
and septicemic E. coli O18:K1:H7 strain H16 and that it influences the expression of virulence-related surface structures in
diverse pathogens (23).
ivi proteins expressed from the E. coli O157 backbone. A
total of 181 ivi proteins of diverse functional classes were
expressed from the backbone (Table 2). Those involved in biosynthesis and metabolism (51.38%) may have functions essential for bacterial growth in vivo, a feature imperative for bacterial pathogenicity. Also, consistent with the anaerobic gut
environment, IVIAT identified glycolytic enzymes, hydrogenases involved in fermentation of carbon compounds, an
alcohol dehydrogenase, and reductases (including two cryptic
nitrate reductases) involved in energy generation from carbohydrates via anaerobic respiration and fermentation (42).
These results were expected and consistent with those of other
studies of diverse organisms using techniques such as transcriptional profiling (59), in vivo expression technology (15, 33), recombinase in vivo expression technology (4), signature-tagged
mutagenesis (14, 37, 38), selective capture of transcribed sequences (SCOTS) (7), and IVIAT of other organisms (5).
Transport ivi proteins (18.78%) included diverse ABC-type
transporters and phosphotransferase systems (PTS), permeases, transport proteins involved in the transport of diverse
molecules, iron uptake proteins such as FhuA (a transporter of
ferrichrome [Fe3⫹] and a receptor for phages and colicins),
CirA, an iron-regulated receptor for uptake and transport of
colicin I, uncharacterized transport proteins, and, in particular,
an anaerobically induced permease, TdcC, expressed from the
tdc operon, which encodes the transport and degradation of
L-threonine and L-serine. Inactivation of the activator, TdcA,
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TABLE 2. Backbone-encoded O157 ivi proteins
General function
and IVIAT
clone

Macromolecule
synthesis
H-5, -20

H-22, -23
H-37
H-40
H-42
H-110
H-121
H-145, -183
H-211
H-230
H-245, -260
H-313
Small-molecule
synthesis
H-11
H-60
H-71
H-116, -137
H-117
H-131, -133
H-132
H-164
H-174
H-177
H-194
H-227
H-267
H-279, -280, -282,
-283, -308, -312
Macromolecule
degradation
H-79
H-99
H-100, -253
H-140, -154, -215,
-218, -219, -222
H-173
H-185
H-188
H-236
H-242
H-304, -307, -309
Small-molecule
degradation
H-7
H-8
H-46, -67
H-58
H-74

topA/DNA topoisomerase type I, omega protein/DNA replication, repair,
restriction/modification
dsbA/protein disulfide isomerase I, essential for cytochrome c synthesis and
formate-dependent reduction/protein translation and modification
crcB/putative protein involved in chromosome condensation
purK/phosphoribosylaminoimidazole carboxylase (AIR carboxylase), CO2fixing subunit/purine ribonucleotide biosynthesis
purD/phosphoribosylglycinamide synthetase (GAR synthetase)/purine
ribonucleotide biosynthesis
apbA/thiamine biosynthesis, alternate pyrimidine biosynthesis
recR/DNA replication, repair, restriction/modification
cysD/ATP:sulfate adenylytransferase, subunit 2
glgP/glycogen phosphorylase/polysaccharide modification
mutH/methyl-directed mismatch repair/DNA replication, repair, restriction/
modification
Z2851/putative Rad3-related DNA helicase
dfp/flavoprotein affecting synthesis of DNA and pantothenate metabolism/
DNA replication, repair, restriction/modification
mutS/methyl-directed mismatch repair/DNA replication, repair, restriction/
modification

ggt/gamma-glutamyltranspeptidase/biosynthesis of cofactors, carriers:
thioredoxin, glutaredoxin, glutathione
Z3637/putative thiamine pyrophosphate-requiring enzyme—isoleucine,
leucine, valine biosynthesis
dapD/2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyl transferase/amino
acid biosynthesis: lysine
glyA/serine hydroxymethyltransferase/amino acid biosynthesis: glycine
accC/acetyl-CoA carboxylase, biotin carboxylase subunit/fatty acid and
phosphatidic acid biosynthesis
hemK/putative protoporphyrinogen oxidase/biosynthesis of cofactors: heme,
porphyrin
alaS/alanyl-tRNA synthetase/tRNA modification
folE/GTP cyclohydrase/biosynthesis of cofactors, carriers: folic acid
nadE/NAD synthetase/biosynthesis of cofactors, carriers: pyridine
hisS/histidine-tRNA synthetase/tRNA modification
Z2789/putative thiosulfate sulfur-transferase
cstC/acetylornithine delta-aminotransferase/amino acid biosynthesis: arginine
lysS/lysine-tRNA synthetase/tRNA modification
proB/gamma-glutamate kinase/amino acid biosynthesis: proline

hycI/protease/processing of C-terminal end of the large subunit of
hydrogenase 3
Z5946/putative restriction endonuclease S subunits
Z3649/putative cellulase M and related protein
dcp/dipeptidyl carboxypeptidase II/degradation of proteins, peptides,
glycopeptides
Z1305/putative ATP-dependent protease
malS/alpha-amylase/degradation of polysaccharides
uvrB/excision nuclease subunit B/degradation of DNA
Z2427/putative metal-dependent amidase/aminoacylase/carboxypeptidase
exo/5⬘–3⬘ exonuclease/degradation of DNA
endA/endonuclease I/degradation of DNA

fadA/thiolase I/degradation of fatty acids
rnt/RNase T/degrades tRNA
xylA/D-xylose isomerase/degradation of carbon compounds
Z0666/putative dihydroorotase and related cyclic amidohydrolases
hflB/integral membrane peptidase/degrades sigma 32

Bacterial-cell
localizationb

Contig
accession
no.

No. of
reactive serac
HUS
sera

Control
serum

Cytoplasm

AE005379

4

0

Periplasm

AE005616

4

0

Inner membrane
Cytoplasm

AE005242
AE005233

4
4

0
0

Cytoplasm

AE005632

4

0

Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

AE005221
AE005487
AE005502
AE005566
AE005512

4
4
4
4
4

0
0
0
0
1

Cytoplasm
Inner membrane

AE005403
AE005591

1
4

0
0

Cytoplasm

AE005501

4

0

Periplasm

AE005568

4

1

Cytoplasm

AE005468

4

0

Cytoplasm

AE005192

2

1

Inner membrane
Cytoplasm

AE005485
AE005553

4
4

0
0

Cytoplasm

AE005338

4

0

Inner membrane
Cytoplasm
Cytoplasm
Inner membrane
Periplasm
Inner membrane
Cytoplasm
Inner membrane

AE005498
AE005447
AE005397
AE005480
AE005398
AE005397
AE005519
AE005202

4
4
4
4
4
4
4
4

0
0
0
1
0
0
0
0

Cytoplasm

AE005500

2

0

Cytoplasm
Cytoplasm
Cytoplasm

AE005666
AE005469
AE005351

2
4
4

0
0
0

Inner membrane
Periplasm
Cytoplasm
Cytoplasm
Inner membrane
Periplasm

AE005285
AE005584
AE005259
AE005372
AE005508
AE005525

2
4
4
4
4
4

0
0
0
0
0
0

Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Inner membrane

AE005615
AE005388
AE005583
AE005232
AE005546

4
4
4
4
4

0
0
0
0
0
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TABLE 2—Continued

General function
and IVIAT
clone

H-91, -93

Energy/metabolism
H-3
H-16
H-19
H-29
H-35
H-39
H-49, -50, -52,
-53, -134
H-54
H-72
H-85
H-88
H-103, -165
H-105
H-108
H-111
H-114, -142
H-118
H-122
H-138
H-147
H-149
H-153
H-160,
H-167
H-171,
H-186
H-205
H-216
H-217,
H-224
H-233,
H-237
H-239
H-244
H-254
H-258
H-270,
H-277
H-287
H-292
H-295
H-300
H-305
H-315

-264
-306

-221, -223
-288

-276

Regulatory
H-1
H-14
H-24
H-27
H-45, -87, -290,
-293
H-81, -83
H-82

Bacterial-cell
localizationb

Contig
accession
no.

No. of
reactive serac
HUS
sera

Control
serum

malY/enzyme that blocks biosynthesis or degrades endogenous Mal inducer,
probably aminotransferase/degradation of carbon compounds
galK/galactokinase/degradation of carbon compounds
celF/phosphor-beta-glucosidase/degradation of carbon compounds
treF/trehalase/degradation of carbon compounds
yciA/putative acyl-CoA hydrolase
malZ/maltodextrin glucosidase/degradation of carbon compounds

Cytoplasm

AE005386

4

0

Inner membrane
Cytoplasm
Inner membrane
Cytoplasm
Inner membrane

AE005253
AE005396
AE005577
AE005342
AE005219

4
4
4
2
4

0
0
0
0
0

yhaF/putative 2,4,-dihydroxyhept-2-ene-1,7-dioic acid aldolase
Z2579/putative dimethyl sulfoxide reductases
Z2779/putative arginine/ornithine N-succinyl transferase beta subunit
fba/fructose-bisphosphate aldolase, class II/glycolysis
Z2723/putative oxidoreductase
hycG/hydrogenase/carbon fermentation
adhP/alcohol dehydrogenase/anaerobic respiration

Cytoplasm
Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

AE005541
AE005382
AE005397
AE005522
AE005392
AE005500
AE005357

4
4
4
4
4
4
4

0
0
0
0
0
0
0

ycaH/putative tetraacyldisaccharide-1-P4⬘-kinase
narW/cryptic nitrate reductase 2, delta subunit/anaerobic respiration
dmsC/dimethyl sulfoxide reductase, subunit C/anaerobic respiration
ccmH/possible subunit of heme lyase/electron transport
ygjL/putative NADPH dehydrogenase
nrfE/formate-dependent nitrite reductases/anaerobic respiration
phoA/alkaline phosphatase/central intermediary metabolism
yhdJ/putative methyltransferase
visC/putative 2-polyprenyl-6-methoxyphenol hydroxylase and related
FAD-dependent oxidoreductases
citF/citrate lyase alpha chain/central intermediary metabolism
yleB/putative 2-polyprenyl-6-methoxyphenol hydroxylase and related
FAD-dependent oxidoreductases
citE/citrate lyase beta chain/central intermediary metabolism
ygfZ/putative aminomethyltransferase related to GcvT
nrdB/ribonucleoside diphosphate reductase, beta subunit, B2/central
intermediary metabolism
agaV/N-acetylgalactosamine-specific IIB component 2 (EIIB-AGA)/central
intermediary metabolism
Z4220/putative dehydrogenase
nuoL/NADH dehydrogenase I, chain L/anaerobic respiration
hybD/probable processing element for hydrogenase-2/anaerobic respiration
nuoM/NADH dehydrogenase I, chain M/anaerobic respiration
Z3775/putative dehydrogenase
Z4018/putative flavodoxin
Z5951/putative GTPase (G3E family)
yhjL/putative oxidoreductase
narY/cryptic nitrate reductase 2, beta subunit/anaerobic respiration
solA/putative sarcosine oxidase-like protein
yidS/putative dehydrogenase (flavoprotein)
ugd/UDP-glucose-6-dehydrogenase/central intermediary metabolism
yliI/putative dehydrogenase
Z3401/putative oxidoreductase
epd/D-erythrose-4-phosphate dehydrogenase/central intermediary metabolism
ybjT/putative dTDP-glucose enzyme
yraL/putative methyltransferase
Z3734/putative metalloprotease
yeaA/putative peptide methionine sulfoxide reductases
wecB/UDP-N-acetyl glucosamine-2-epimerase/central intermediary metabolism
tktA/transketolase 1 isoenzyme/central intermediary metabolism
pflD/formate acetyltransferase 2/anaerobic respiration

Cytoplasm
Cytoplasm
Inner membrane
Inner membrane
Inner membrane
Inner membrane
Periplasm
Cytoplasm
Inner membrane

AE005281
AE005359
AE005279
AE005452
AE005538
AE005640
AE005217
AE005554
AE005521

4
4
4
4
4
4
4
4
4

1
0
0
1
0
0
1
0
0

Inner membrane
Inner membrane

AE005241
AE005245

4
4

0
0

Inner membrane
Cytoplasm
Cytoplasm

AE005241
AE005520
AE005456

4
4
4

0
0
0

Inner membrane

AE005542

4

0

Inner membrane
Inner membrane
Inner membrane
Inner membrane
Outer membrane
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Periplasm
Cytoplasm
Inner membrane
Periplasm
Inner membrane
Cytoplasm
Inner membrane
Cytoplasm
Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

AE005518
AE005460
AE005529
AE005459
AE005480
AE005499
AE005666
AE005579
AE005359
AE005316
AE005600
AE005428
AE005265
AE005446
AE005523
AE005268
AE005543
AE005477
AE005401
AE005610
AE005524
AE005626

4
4
4
4
4
4
4
4
4
2
4
4
4
4
4
4
4
4
4
4
4
4

0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

basS/BasS/sensor protein for BasR, involved in macromolecule synthesis
phoQ/PhoQ/sensor protein; global regulation
mopB/GroES chaperone/folding and ushering proteins
pqiA/paraquat-inducible protein A/not characterized
xylR/XylR/regulates the xyl operon, involved in xylose utilization

Inner membrane
Inner membrane
Cytoplasm
Inner membrane
Cytoplasm

AE005644
AE005328
AE005648
AE005285
AE005583

4
4
2
4
4

0
0
0
1
0

ydeW/putative transcriptional regulator
glnG/GlnG/response regulator for gln operon, involved in glutamine
biosynthesis; interacts with sensor GlnL

Inner membrane
Cytoplasm

AE005353
AE005617

4
4

0
0
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TABLE 2—Continued
General function
and IVIAT
clone

H-86

H-127
H-141
H-159
H-192
H-193
H-195
H-201
H-256
H-262
H-274
H-278
H-297
H-303
H-311
Transport
H-4, -289
H-10
H-12
H-15
H-28
H-31
H-34
H-44, -200, -213,
-250, -251, -286
H-47, -66, -266
H-59
H-73
H-76
H-92
H-101
H-109, -168, -169,
-172, -182, -184
H-115
H-125, -275
H-126
H-143
H-163
H-176
H-187
H-197
H-202, -261
H-206
H-225
H-226
H-228
H-240
H-252
H-271
H-273
H-296
H-316

rcsF/RcsF/regulates the rcs regulon, involved in colanic acid synthesis;
interacts with rcsB
yieP/putative transcriptional regulator
glnL/GlnL/histidine protein kinase sensor for the GlnG regulator; glutamine
biosynthesis
yifB/putative 2-component regulator
uidR/UidR/regulates the uid operon, involved in beta-glucuronidase synthesis
prpR/PrpR/regulates the prp operon, involved in propionate catabolism
yfeR/putative transcriptional regulator, LysR type
uvrY/putative 2-component regulator
ybcZ/putative 2-component sensor
yeiL/putative transcriptional regulator
yifA/putative transcriptional regulator
fucR/FucR/positive regulator of the fuc operon
fliS/FliS/regulates flagellar biosynthesis
hydH/HydH/sensor kinase for HydG, hydrogenase 3 activity
narX/NarX/nitrate/nitrate sensor, histidine protein kinase, acts on NarL
regulator
yhjC/putative transcriptional regulator, LysR type
Z2724/putative Arac-type regulator
ascF/AscF; PTS system enzyme II/transport of small molecules: arbutin,
salicin, cellobiose
ybhS/putative ABC-type multidrug transport system, permease component
wzxC/putative export protein; protein, peptide secretion
⬘flhB/export of flagellar proteins
yohM/putative ABC-type uncharacterized transport system, permease component
tdcC/TdcC; anaerobically induced permease/transport of amino acids:
L-threonine, L-serine
malF/MalF; permease/transport of small molecules: maltose
yegT/putative nucleoside permease
ycbQ/putative chaperone
yedE/putative transport system permease protein
Z4150/putative transport protein
yhfC/putative transport protein
yaeM/putative ATP-binding component of transport system
Z2654/putative chaperone distantly related to HSP70-fold metalloprotease
livG/LivG; ATP-binding component of high-affinity branched-chain amino
acid transport system/transport of amino acids, amines
ugpC/UgpC; ATP-binding component of glycerol-3-phosphate transport system/transport of small molecules: carbohydrates, organic acids, alcohols
ycdG/putative xanthine/uracil permease
kefC/KefC/transport of cations: K⫹ efflux antiporter, glutathione regulated
Z3262/putative ADP-ribosylglycohydrolase
yhfM/putative amino acid/amine transport protein
Z5178/putative PTS component; transport of carbohydrates, organic acids,
alcohols
wzb/putative tyrosine phosphatase
kgtP/KgtP; alpha-ketoglutarate permease/transport of small molecules:
carbohydrates, organic acids, alcohols
fhuA/FhuA/transport of ferrichrome (Fe3⫹) and antibiotics, acts as a
receptor for phages and colicins
nagE/NagE; PTS system N-acetylglucosamine-specific enzyme IIABC/
transport of amino acids, amines
sgaB/putative PTS, galactitol-specific IIB component
Z2786/putative ABC-type uncharacterized transport system, periplasmic
component
yaaU/putative transport protein
cycA/CycA; permease/transport of amino acids and amines: D-alanine,
D-serine, glycine
oppB/OppB; oligopeptide transport permease protein/transport of large
molecules: proteins, peptides
Z5839/putative ATP-binding component of ABC-type transport system
Z3589/putative transporting ATPase
araG/AraG; ATP-binding component of high-affinity L-arabinose transport
system/transport of small molecules: L-arabinose
Z2605/putative arginine/ornithine antiporter

Bacterial-cell
localizationb

Contig
accession
no.

No. of
reactive serac
HUS
sera

Control
serum

Outer membrane

AE005195

4

0

Cytoplasm
Inner membrane

AE005607
AE0055617

4
4

1
1

Periplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Inner membrane
Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Inner membrane
Inner membrane

AE005608
AE005385
AE005212
AE005471
AE005414
AE005236
AE005448
AE005607
AE005508
AE005415
AE005632
AE005339

4
4
4
4
4
4
4
4
4
4
4
2

1
0
1
0
0
0
0
0
0
0
0
0

Inner membrane
Cytoplasm

AE005577
AE005392

4
4

0
0

Inner membrane

AE005500

4

0

Inner
Inner
Inner
Inner
Inner

membrane
membrane
membrane
membrane
membrane

AE005260
AE005430
AE005410
AE005437
AE005540

4
4
4
4
4

1
0
0
0
0

Inner membrane
Inner membrane

AE005636
AE005436

4
4

0
0

Outer membrane
Inner membrane
Inner membrane
Inner membrane
Inner membrane
Cytoplasm
Cytoplasm

AE005284
AE005415
AE005512
AE005559
AE005193
AE005387
AE005569

4
4
4
4
4
4
4

0
0
0
0
0
0
0

Cytoplasm

AE005568

4

0

Inner
Inner
Inner
Inner
Inner

membrane
membrane
membrane
membrane
membrane

AE005300
AE005181
AE005436
AE005560
AE005600

4
4
4
2
4

0
0
0
0
0

Inner membrane
Inner membrane

AE005432
AE005489

4
4

0
0

Outer membrane

AE005191

4

0

Inner membrane

AE005246

4

0

Cytoplasm
Periplasm

AE005652
AE005398

4
4

0
0

Inner membrane
Inner membrane

AE005181
AE005653

4
4

0
0

Inner membrane

AE005342

4

0

Inner membrane
Cytoplasm
Inner membrane

AE005655
AE005464
AE005411

4
4
2

0
0
1

Inner membrane

AE005384

4

0
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TABLE 2—Continued

General function
and IVIAT
clone

H-36
H-41, -130, -152, -265
H-55
H-62, -63, -64, -65
H-77
H-95
H-96
H-150
H-203
H-234
H-246
H-268
H-281
H-284
H-302
Phage related
H-209
H-238
Unknown
H-43, -208, -291
H-57
H-68, -69
H-80
H-97
H-157
H-170
H-179
H-190
H-198
H-212
H-243

Bacterial-cell
localizationb

Contig
accession
no.

Inner membrane
Periplasm
Inner membrane
Inner membrane
Periplasm
Inner membrane
Cytoplasm
Outer membrane
Inner membrane
Inner membrane
Outer membrane
Inner membrane
Inner membrane

No. of
reactive serac
HUS
sera

Control
serum

AE005363

4

0

AE005668
AE005634
AE005185
AE005464
AE005234
AE005192
AE005447

4
4
4
4
4
4
4

0
0
0
0
0
0
0

AE005577
AE005454
AE005498

4
4
3

1
0
0

AE005670
AE005667

4
4

0
0

Cytoplasm
Inner membrane
Outer membrane

AE005266
AE005588
AE005202

4
4
4

0
0
0

Z1782/unknown, encoded within CP-933N
hflX/GTP-binding subunit of protease specific for lambda cII repressor/
degradation of proteins, peptides, glycopeptides

Inner membrane
Cytoplasm

AE005323
AE005650

4
2

0
0

yfiH/uncharacterized conserved protein
ydbD/unknown
ychA/uncharacterized conserved protein
yfbB/putative enzyme
ybfE/unknown
yacC/unknown
Z4888/unknown
yciI/unknown
yjjX/unknown
yaaH/unknown
ybiM/unknown
Z2619/unknown

Cytoplasm
Periplasm
Cytoplasm
Inner membrane
Cytoplasm
Cytoplasm
Inner membrane
Inner membrane
Cytoplasm
Inner membrane
Inner membrane
Outer membrane

AE005490
AE005365
AE005338
AE005458
AE005246
AE005188
AE005573
AE005342
AE005670
AE005177
AE005261
AE005385

4
4
4
2
4
4
4
4
2
4
4
4

0
0
0
0
1
0
0
0
0
0
1
0

trg/Trg; methyl-accepting chemotaxis protein III, ribose sensor receptor/
regulator; chemotaxis and motility
osmY/OsmY; hyperosmotically inducible protein/osmotic adaptation
yjbB/putative alpha-helix protein
ftsI/peptidoglycan synthetase/septum formation
mepA/murein D,D-endopeptidase/cell envelope synthesis
sfmH/SfmH/fimbrial assembly
yaeH/putative structural protein
cirA/CirA/receptor for iron-regulated colicin I
yhjD/putative membrane protein
Z3481/putative membrane protein
mltB/membrane-bound lytic murein transglycosylase B/murein sacculus
synthesis
slt/soluble lytic murein transglycosylase/murein sacculus synthesis
tsr/methyl-accepting chemotaxis protein I, serine sensor receptor/regulator,
chemotaxis and motility
mdaA/MdaA/modulator of drug activity A
yibP/putative membrane protein
phoE/PhoE/outer membrane porin protein E

a
Based on homology to the sequenced E. coli O157 strain EDL933 genome. Putative functions of hypothetical proteins were determined from the COGs database
when available.
b
Predicted by the PSORT/PSORT-B program.
c
Sera from four patients with HUS and one healthy person were tested individually.

results in hyperadherence of E. coli O157 to cultured epithelial
cells due to derepression of OmpA expression (54).
Regulatory proteins (13.81%) comprised, among others,
QseA, a LysR-type transcriptional activator (described above)
(52), and several two-component regulatory systems that govern the virulence of diverse pathogens (17). Some of these are
functionally interlinked, as evidenced by earlier reports (8, 10,
16, 58) and the Prolinks database, suggesting that IVIAT identified proteins that sense and integrate diverse environmental
signals (such as anaerobiosis, cation limitation, acid, and excess, toxic levels of extracytoplasmic Fe3⫹) and help E. coli
O157 mount a coordinated cellular adaptive response to counter
the hostile host environment. The two-component regulatory
systems IVIAT identified were (i) the sensor molecule, NarX,
of the NarL-NarX system, which in the absence of oxygen

responds to nitrate or nitrite and acts via NarL, the response
regulator that activates expression of enzymes involved in nitrate respiration and represses enzymes involved in respiration
of other electron acceptors (27, 46); (ii) the sensor kinase
component, PhoQ, of the PhoP-PhoQ system, which responds
to extracytoplasmic levels of Mg2⫹ and Ca2⫹ (involved in the
adaptation to Mg2⫹ limitation) (8) and to Zn2⫹ excess (10);
(iii) the sensor component, BasS, of the BasR-BasS system,
which governs the response to excess extracytoplasmic Fe3⫹
(58) and mild acid pH (51); (iv) the sensor protein, GlnL, of
the GlnG-GlnL system, which responds to low ammonia concentrations and stimulates ammonia assimilation (40); and (v)
HydH, the sensor for HydG, which primarily responds to high
periplasmic Zn2⫹ and Pb2⫹ concentrations and nonspecifically
activates the expression of hydrogenase 3, an enzyme involved
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Environmental adaptation (chemotaxis,
motility, attachment, cell division)
H-30
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in the degradation of nontransportable organophosphates (40).
The PhoB regulon is required for colonization of the rabbit
small intestine by V. cholerae (55) and regulates hilA and invasion genes in Salmonella serovar Typhimurium (31). A possible role in E. coli O157 virulence is also suggested by the fact
that in vivo expression of PhoB in an avian-pathogenic E. coli
(APEC) strain during experimental infection of chickens was
identified by SCOTS (7).
Phage-related proteins (1.11%) included an inner membrane protein of unknown function and a nonspecific protease
that degrades the lambda repressor cII. Proteins of unknown
function (6.08%) rounded off ivi proteins expressed from the
backbone. Collectively, these results suggested that defined
backbone ivi proteins not only support pathogenicity by facilitating in vivo survival but also regulate and indirectly complement pathogen-specific virulence factors.
ivi proteins expressed from OIs. The 37 ivi proteins expressed from OIs included 13 phage-related proteins (Table
3). Because phage proteins include both Stx1 and Stx2 in
EHEC, and because they also include proteins that influence
every stage of infection of mammalian hosts by diverse pathogens (56), they are potential virulence factors and warrant
further evaluation. Although IVIAT did not identify either
Stx1 or Stx2 (both are also produced during in vitro growth in
LB broth) (47), it identified two homologous ivi proteins of
unknown function, one expressed from each of the phages that
encode Stx1 and Stx2. These two ivi proteins are homologous
to ivi proteins expressed from several other cryptic prophages
(Table 3).
Particularly interesting was the fact that certain OIs (OIs 36
and 71) containing cryptic prophages expressing ivi proteins
also expressed nonphage, non-LEE (Nle) effectors (proteins
encoded outside the LEE but secreted via the type III secretion apparatus encoded on the LEE) (6). The presence of Nle
homologs, such as NleA and NleF (OI 71) and NleB, NleC,
and NleD (OI 36), in related pathogens and the requirement of
NleA for full virulence of Citrobacter rodentium, a pathogen of
mice, suggest a probable role for phage proteins expressed
from these OIs in E. coli O157 virulence (9).
IVIAT identified 24 clones whose inserts encoded proteins
expressed from OI sequences that are not part of phage genomes (Table 3). These included intimin-␥, expressed from the
LEE (OI 148); WbdP, a cytoplasmic glycosyltransferase (OI
84) involved in the synthesis of the O-polysaccharide antigen
(57); WaaD, a putative periplasmic glycosyltransferase (OI
145) involved in biosynthesis of the oligosaccharide core of
LPS; and numerous ivi proteins with putative or unknown
functions (Table 3). The identification of enzymes involved in
both O-antigen and LPS core biosynthesis by IVIAT was expected, because LPS is a broadly recognized virulence determinant of pathogenic gram-negative bacteria, and transcripts
of genes encoding such enzymes were identified during infection of chickens with APEC by using SCOTS (7). Other nonphage ivi proteins that could impact E. coli O157 virulence
included a putative arylsulfatase (OI 40) involved in the scavenging of sulfate and implicated in the ability of E. coli K1 to
invade brain microvascular endothelial cells (18) and a putative recombinant hot spot A (RhsA) protein (OI 30) that
reportedly contributes to genomic plasticity (30). Transcripts
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in hydrogen production during fermentation (28). IVIAT also
identified an outer membrane lipoprotein, RcsF, that transduces a signal in response to glucose and zinc to the RcsC/
YojN/RcsB/RcsA phosphorelay system, which in turn controls
the rcs regulon (target genes), encoding enzymes for the colanic acid exopolysaccharide capsule (10), an acid-adaptive response that protects E. coli O157 from environmental stresses
such as acid and heat (34). Other ivi proteins that were part of
this functional group and likely to impact in vivo survival of
E. coli O157 were (i) PrpR, a regulator of the prp operon involved in the catabolism of propionate, a short-chain fatty acid
(SCFA) that can be detrimental to E. coli O157 at high concentrations (exposure to SCFA is a stress condition, and catabolism may serve to decrease the concentration of this SCFA
[26, 45]); (ii) FucR, a positive regulator of the fuc operon encoding enzymes for metabolism of L-fucose, a component of
both mucus and glycans on enterocytes (42) (following experimental inoculation of mice, E. coli O157 reportedly is found
attached to both mucus and enterocytes [in contrast to nonpathogenic E. coli, which is found in mucus alone] [39] and
may utilize L-fucose as one nutrient source to multiply and
outcompete other flora to establish infection); (iii) FliS and
FliT, which along with FliD negatively regulate the export of
the anti-sigma factor, FlgM, to prevent expression of the flagellar regulon (which may promote in vivo survival, since overproduction of flagella is deleterious to bacterial growth) (61);
and (iv) paraquat-inducible protein A (PqiA), an inner membrane protein of uncharacterized function.
ivi proteins functioning in environmental adaptation (8.84%)
included methyl-accepting chemotaxis proteins (MCPs), a protein that was part of the adaptive response to hyperosmolarity,
a colicin expressed in response to iron-limiting conditions, a
modulator of drug activity, and two proteins of the PhoB regulon expressed as part of the adaptive response to phosphate
limitation. Specifically, IVIAT identified two MCPs, namely,
Trg, a receptor for the periplasmic ribose and galactose binding proteins, and Tsr, the serine sensor receptor, both of which
are regulators of chemotaxis and motility (40). Interestingly,
MCPs were also highly expressed during human infection with
V. cholerae as identified by IVIAT (12). IVIAT also identified
OsmY, a periplasmic protein of unknown function that is induced in response to hyperosmolarity (60). This protein is
expressed as part of the Rcs regulon, which includes genes
encoding the synthesis of the exopolysaccharide colanic acid
capsule (see above) and possibly functions in the transport of
an alternative osmolyte (10). One of the ivi proteins in this
subgroup was CirA, an iron-regulated receptor for colicin homologous to a siderophore iron uptake system, which is also
expressed under iron-limiting conditions by other pathogens
such as Salmonella enterica serovar Typhimurium (16). Interestingly, as in previous studies (16, 58), IVIAT identified proteins expressed in response to iron limitation (FhuA and
CirA), as well as those expressed in response to extracytoplasmic iron excess (BasS of the BasR-BasS two-component system; see above). Other ivi proteins included MdaA, a modulator of drug activity, and two proteins that are part of the Pho
regulon and are expressed as part of the adaptive response to
limiting phosphate in the environment, namely, PhoE, an outer
membrane porin functioning in the transport of various anions,
and a periplasmic phosphate ester hydrolase, PhoA, involved
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TABLE 3. OI- and pO157-encoded O157 ivi proteins

IVIAT clone

Assigned function:
H-285

H-17

No. of
reactive serac
HUS
sera

Control
serum

wbdP/glycosyltransferase/cell surface polysaccharides and antigen
synthesis

Cytoplasmic

AE005429

4

0

OI 47

Z1554/putative ABC transport, lipoprotein release, permease
component/cell wall biogenesis
Z0634/putative cytoplasmic membrane, ABC-type bacteriocin/
lantibiotic exporter/defense mechanism
Z3936/putative transposase, IS30 family
Z1214/predicted esterase of the alpha-beta hydrolase superfamily
Z5901/putative helicase with a unique C-terminal domain including
metal-binding cysteine cluster
Z0348/putative arabinose efflux permease/carbohydrate transport
Z0419/putative ABC-type transport permease
waaD/putative lipopolysaccharide biosynthesis enzyme (glycosyltransferase)
Z4856/putative acyl-CoA synthetase/AMP-(fatty) acid ligase
L7004/putative hemolysin expression-modulating protein—
hypothetical protein
Z5415/predicted permease
Z0705/putative RhsA/Rhs family protein
L7091/putative nickase
Z1089/putative arylsufatase A
Z5888/predicted transcriptional regulator
Z4882/uncharacterized protein encoded in hypervariable junctions
of pilus gene clusters
sopA/putative plasmid partitioning protein A

Inner membrane

AE005305

4

0

Inner membrane

AE005229

4

0

Cytoplasm
Cytoplasm
Cytoplasm

AE005493
AE005276
AE005661

4
4
4

0
0
0

Inner membrane
Inner membrane
Periplasm

AE005205
AE005211
AE005590

2
4
4

0
0
0

Inner membrane
Cytoplasm, inner
membrane
Inner membrane
Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

AE005571
AF074613

4
4

0
1

AE005619
AE005236
AF074613
AE005267
AE005659
AE005572

2
4
4
4
4
4

0
0
0
1
0
0

Inner membrane

AF074613

4

0

Z1930/putative hydrolase or acyltransferase (alpha/beta hydrolase
family), encoded within CP-933X
Z1883/putative DNA-packaging protein encoded within CP-933X
Z0964/putative DNA-packaging protein encoded within CP-933K
Z1433/unknown, encoded within BP-933W
Z1882/putative phage DNA-packaging protein, NU1 subunit of
terminase, encoded in CP-933X
Z1888/putative capsid protein of prophage CP-933X
Z2085/putative exonuclease VIII, encoded within CP-933O
Z3327/unknown, encoded within CP-933V
Z6060/putative Q anti-terminator encoded within CP-933P
Z3334/unknown, encoded within CP-933V
Z2100/unknown, encoded within CP-933O
Z0975/putative tail component of CP-933K
Z3097/putative peptidase—putative head-tail connector protein
encoded within CP-933U

Inner membrane

AE005334

4

1

Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm

AE005330
AE005256
AE005295
AE005330

4
4
4
4

0
1
0
0

Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Cytoplasm
Inner membrane
Inner membrane
Inner membrane,
cytoplasm

AE005330
AE005346
AE005441
AE006460
AE005442
AE005347
AE005257
AE005420

4
4
4
3
4
4
4
4

0
0
0
0
1
0
0
0

Z5897/unknown
Z0251/unknown (uncharacterized protein conserved in bacteria)
Z5002/unknown (uncharacterized protein conserved in bacteria)
Z3271/unknown
Z3269/unknown
Z4912/unknown
Z3616/unknown
Z1606/unknown

Inner membrane
Cytoplasm
Cytoplasm
Inner membrane
Cytoplasm
Cytoplasm
Cytoplasm
Inner membrane

AE005660
AE005198
AE005584
AE005436
AE005436
AE005576
AE005466
AE005309

4
4
4
4
4
3
4
4

0
0
0
0
0
0
0
0

OI 28

H-25
OI 108
H-33
OI 43
H-48, -51, -89, -90 OI 172
H-78
H-84
H-98

OI 9
OI 17
OI 145

H-102
H-113

OI 138
pO157

H-129
H-135
H-136
H-151
H-231
H-263

OI 157
OI 30
pO157
OI 40
OI 172
OI 139

H-298

pO157
OI 52

H-38, -56
H-70
H-106
H-112

OI
OI
OI
OI

52
36
45d
52

H-128
H-139
H-158
H-191
H-196
H-247
H-255, -257
H-272

OI
OI
OI
OI
OI
OI
OI
OI

52
57
93
71d
93d
57d
36
79d

OI
OI
OI
OI
OI
OI
OI
OI

172
7
142
89
89
140
102
48d

Unknown
H-2
H-21
H-107
H-119
H-123
H-146
H-162
H-269

Contig/plasmid
accession no.

OI 84

d

Phage related
H-18

Gene/protein/function

Bacterial-cell
localizationb

a

a

Putative functions of hypothetical proteins determined from the COGs database when available.
Predicted by the PSORT/PSORT-B program.
Sera from four patients with HUS and one healthy person were tested individually.
d
Homologous proteins also found on other OIs.
b
c

of a gene encoding RhsH, a similar protein, were also detected
during APEC infection of chickens by SCOTS (7).
Many nonphage ivi proteins were expressed from seven of
the nine large OIs (⬎15 kb) that reportedly encode putative
virulence factors (Table 4) (44). Besides intimin-␥ from OI
148, IVIAT also identified a putative acyl coenzyme A (CoA)
synthetase (fatty acid:CoA ligase), expressed from OI 138,

which catalyzes the formation of fatty acyl-CoA, a substrate for
phospholipid biosynthesis and enzymes of ␤-oxidation, and is
involved in diverse functions such as protein transport, protein
acylation, enzyme activation, cell signaling, and control of transcription (40); a putative inner membrane ABC-type transport
permease expressed from OI 47 and functioning in cell wall
biogenesis; a putative inner membrane ABC-type bacteriocin/
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TABLE 4. ivi proteins expressed from OIs encoding putative virulence factors
OI

Putative virulence factor

Macrophage toxin and a chaperone
An RTX-toxin-like exoprotein and transport system

OI
OI
OI
OI

Urease gene cluster
Adhesin and polyketide or fatty acid biosynthesis system
Urease gene cluster
TTSSa and secreted proteins similar to Samonella-Shigella
Inv-Spa host cell invasion proteins
Two toxins and a PagC-like virulence factor
Fatty acid biosynthesis system
LEE proteins

43
47
48
115

OI 122
OI 138
OI 148
a

Z0251/unknown
Z0634/putative cytoplasmic membrane ABC-type bacteriocin/lantibiotic
exporter
Z1214/a predicted esterase
Z1554/putative ABC-type transporter
Z1606/unknown
None identified
None identified
Z4856/putative acyl-CoA synthetase/fatty acid ligase
Eae/␥-intimin/attaching and effacing

TTSS, type III secretion system.

lantibiotic exporter expressed from OI 28 that functions in the
export of large molecules such as proteins and peptides and is
homologous to ATP-binding proteins of ABC transporters and
toxin secretion systems of several pathogens, including Pseudomonas putida, Salmonella enterica serovar Typhi, and V. cholerae; a cytoplasmic esterase of the ␣-␤ hydrolase superfamily
expressed from OI 43; a conserved cytoplasmic protein of
unknown function expressed from OI 7; and an inner membrane protein of unknown function expressed from OI 48.
Interestingly, IVIAT did not identify clones expressing putative virulence factors encoded on OI 115 and OI 122 (Table 4).
Perhaps these proteins are expressed equally in vitro and in
vivo, resulting in the removal of corresponding reactive antibodies during adsorption, or these proteins are not immunogenic, or antibodies to these proteins are short-lived.
ivi proteins expressed from pO157. ivi proteins expressed
from pO157 (Table 3) included the previously discussed TagA
and MsbB2; SopA, an ATPase that accurately partitions lowcopy-number F plasmids into daughter cells (also identified
during APEC infection of chickens) (7); a putative nickase
associated with plasmid maintenance; and a putative hemolysin expression-modulating protein, a homolog (90% amino

acid identity) of the E. coli regulator Hha (3), which complexes
with the nucleoid-associated universal regulator protein H-NS
and governs expression of the hly operon in response to
changes in temperature and osmolarity (32). In addition, Hha
has also been shown to repress the LEE-encoded regulator
(Ler) in E. coli O157, thereby causing reduced expression of
the esp operon encoding the LEE translocator proteins EspA,
EspB, and EspD (49).
A majority of clones expressing ivi proteins reacted specifically and broadly with HUS convalescent-phase serum samples from individual patients. ivi proteins for practical applications, such as the development of diagnostic markers,
vaccines, and drugs, should ideally be expressed strongly during infection and evoke robust immune responses broadly in
patients with E. coli O157 disease. The majority of the 223
positive clones identified earlier using pooled adsorbed HUS
convalescent-phase sera reacted with each of the four individual serum samples that made up the pool but not with a control
serum sample taken from a healthy pediatric patient (Tables 1,
2, and 3). However, 15 ivi proteins expressed from the backbone and four ivi proteins expressed from OIs reacted differentially with individual patient serum samples. We are cur-

TABLE 5. O157 backbone ivi proteins expressed in vitro as identified by proteomic analysis

Protein no.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
a

O157 ivi protein

Z4279
Z5747
Z4263
Z4540
Z4616
Z4228
Z0176
Z3999
Z2789
Z3827
Z5977
Z3777
Z5955
Z3491
Z4043
Z4478
Z0998
Z5392

transketolase 1 isozyme (tktA)
GroES, 10-kDa chaperone binds to Hsp60 (mopB)
fructose-bisphosphate aldolase, class II (fba)
degrades sigma 32, integral membrane peptidase, cell division (hflB)
acetyl-CoA carboxylase, biotin carboxylase subunit (accC)
lysine tRNA synthetase, constitutive suppressor of ColE1 (lysS)
2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase (dapD)
alanyl-tRNA synthetase (alaS)
putative thiosulfate sulfur transferase
serine hydroxymethyltransferase (glyA)
hyperosmotically inducible periplasmic protein (osmY)
histidine tRNA synthetase (hisS)
methyl-accepting chemotaxis protein I, serine sensor receptor (tsr)
ribonucleoside diphosphate reductase 1, beta subunit, B2 (nrdB)
methyl-directed mismatch repair (mutS)
ORF, hypothetical protein (yhaF)
DNA repair excision nuclease subunit B (uvrB)
protein disulfide isomerase I, essential for cytochrome (dsbA)

Two 4-h runs were done using this denaturing condition. Each yielded more than 300 proteins.

Result with 6 M urea and
1% SDS denaturing
solutiona
Run 1

Run 2

⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫺
⫹
⫺
⫹

⫹
⫹
⫹
⫺
⫺
⫹
⫹
⫹
⫺
⫹
⫹
⫹
⫹
⫹
⫹
⫺
⫹
⫹

% Protein
abundance

0.49
0.32
0.28
0.17
0.14
0.13
0.11
0.11
0.10
0.09
0.08
0.07
0.06
0.06
0.05
0.05
0.05
0.04
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rently investigating via PCR whether the failure of individual
patients to respond to a particular ivi protein is attributable to
heterogeneity of cognate isolates. Also, 22 backbone (Table 2)
and 2 E. coli O157-specific (Table 3) ivi proteins reacted with
the control serum. We speculate that this may be due to crossreacting antibodies in the control sera or to the presence of
preexisting antibodies to O157 proteins from prior, unrecog-

nized infection. Studies are ongoing to compare the reactivities
of sera from healthy individuals of different age groups to the
ivi antigens.
ivi proteins expressed from OIs and pO157 were not among
the 300 O157 proteins most highly expressed during in vitro
growth. The central premise of IVIAT is that the proteins
identified are expressed specifically during infection but not
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FIG. 3. Graphical representation of the locations of ivi genes on the chromosome of E. coli O157 strain EDL933. Outer and inner circles show
the positions of ivi genes on the backbone and OIs, respectively. The black numbers on the outside of the inner circle refer to individual OIs (44).
Individual OI genes, phage-associated genes, the LEE (encoding intimin-␥), CP-933V (encoding Stx1), and BP-933W (encoding Stx2) are also
shown. OI groups, I, II, and III are indicated (see the text). The innermost circle shows the scale in base pairs. This figure was created using
Genvision software from DNASTAR.

VOL. 73, 2005

during growth under standard laboratory conditions. Proteomic analysis using ESILC-MS/MS confirmed that none of the
37 ivi proteins expressed from OIs and none of the 5 expressed
from pO157 were among the 300 O157 proteins most highly
expressed during growth in LB broth (data not shown). This
was not entirely expected, because some of the E. coli O157specific proteins are reportedly expressed, at least to some
degree, in vitro (36). We speculate that, owing to low-level
expression of such proteins during in vitro culture, an MS run
of longer duration would be required for their identification.
In contrast, 18 of 181 backbone ivi proteins were expressed
sufficiently in LB broth for detection by proteomic analysis
(Table 5). Of these 18 backbone ivi proteins expressed in vitro,
12 were identified by ESILC-MS/MS during the course of
both runs; 6 of which were weakly expressed at a percent
protein abundance ranging from 0.09 to 0.04%, and the remaining 6 were expressed in only one run (Table 5). We hypothesize that these 18 proteins are expressed at higher levels
during human infection than during growth in LB broth and
attribute their identification by IVIAT to the fact that low-level
protein expression during in vitro growth may not effectively
deplete HUS convalescent-phase sera of antibodies against
these ivi proteins during absorption.
Graphical representations of the locations of ivi genes on the
E. coli O157 chromosome and on the pO157 plasmid are
shown in Fig. 3 and 4, respectively. ivi genes included 181 of
4,029 (4.5%) open reading frames (ORFs) in the backbone, 37
of 1,387 (2.7%) ORFs in the OIs, and 5 of 100 (5%) ORFs in
pO157 sequences of the EDL933 genome (44).
The 181 backbone-specific ivi genes were distributed uniformly on the E. coli O157 chromosome; however, several of
the 37 OI-specific ivi genes appeared to localize in three discrete OI groups (a group contained four or more OIs, with
each separated by five or fewer intervening OIs). Although
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in most cases only one ivi gene mapped to an individual OI,
there were instances where multiple ivi genes (two or more)
mapped within the same OI (OI 36, OI 52, OI 57, OI 89, OI
93). The five ivi genes that mapped to pO157 are also shown
in Fig. 4.
The apparent grouping of OIs expressing ivi proteins raises
the possibility that ivi proteins (and other proteins) expressed
from OIs within a particular group might act in concert to
optimally influence a specific function. Particularly interesting
was the fact that group I, which included OI 148, expressing the
adhesin intimin-␥, also included OI 145, expressing the glycosyltransferase WaaD, one of the many enzymes involved in the
biosynthesis of LPS core oligosaccharide. The facts that WaaD
is expressed from the same operon as WaaI (another enzyme
that functions in LPS core oligosaccharide biosynthesis) and
that E. coli O157 waaI deletion mutants are hyperadherent to
cultured intestinal epithelial cells (54) may suggest that during
human infection, intimin-␥ and E. coli O157 LPS (and possibly
other ivi and non-ivi proteins, expressed from OIs within this
group) might act in concert to modulate the adherence of
E. coli O157 to human epithelial cells. It will be interesting to
test this hypothesis experimentally and also to determine
whether proteins in OI groups II and III might be functionally
related as well.
In conclusion, IVIAT identified 223 O157 proteins expressed in vivo during human infection, several of which were
unique to this study. Judged by our results, IVIAT enables
identification both of proteins expressed specifically during
human infection but not during growth under standard laboratory conditions and of proteins expressed at significantly
higher levels in vivo than in vitro. Although IVIAT for E. coli
O157 was validated by the identification of previously identified potential E. coli O157 virulence factors, prior infection
with E. coli O157 does not necessarily produce full protection
from subsequent reinfection (1). This may reflect suboptimal
antibody responses to protective antigens, and we hypothesize
that robust expression and optimal delivery of relevant ivi
proteins (and other O157 antigens) to the mucosal immune
system might engender more-protective immune responses.
Preliminary experiments demonstrated that all of the 223 reactive clones also reacted with pooled adsorbed sera from
patients who had recovered from hemorrhagic colitis (data not
shown), suggesting that similar pathogenic mechanisms may be
operating in this illness and HUS.
IVIAT provides a “snapshot” of O157 protein expression
during infection and a glimpse of the possible mechanisms by
which this pathogen might counter host defenses and adapt
and establish itself within the human gut to cause disease.
Studies directed toward the characterization of the role of ivi
proteins in E. coli O157 pathogenesis are currently under way.
The identification of ivi genes unique to diverse E. coli O157
isolates, as well as identification of those unique to non-O157
EHEC or to Shiga-toxigenic E. coli (STEC), which lacks LEE
but is pathogenic to humans, and of ivi genes shared between
EHEC and EPEC (unpublished data), augurs well for the
future development of diagnostic tests for EHEC and STEC
infection, as well as for the development of common drugs and
vaccines against EHEC, STEC, and EPEC.
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FIG. 4. Graphical representation of the locations of ivi genes on
the pO157 plasmid of E. coli O157 strain EDL933. The outer circle
shows the positions of ivi genes (magenta), and the inner circle, the
scale in base pairs. This figure was created using Genvision software
from DNASTAR.

O157 GENES INDUCED DURING HUMAN INFECTION

2678

JOHN ET AL.

INFECT. IMMUN.

ACKNOWLEDGMENTS
This work was supported by grants R03 AI53700-01 and R21
AI055963 (to I.T.K.), R01 DE13523 (to M.H.), and R01 DK52081 and
R01 AI47499 (to P.I.T.) from the National Institutes of Health.

25.

REFERENCES
26.
27.

28.
29.
30.
31.

32.

33.
34.
35.
36.

37.
38.
39.

40.

41.

42.
43.

44.

45.
46.

Downloaded from http://iai.asm.org/ on February 8, 2014 by Washington University in St. Louis

1. Besser, R. E., P. M. Griffin, and L. Slutsker. 1999. Escherichia coli O157:H7
gastroenteritis and the hemolytic uremic syndrome: an emerging infectious
disease. Annu. Rev. Med. 50:355–367.
2. Bowers, P. M., M. Pellegrini, M. J. Thompson, J. Fierro, T. O. Yeates, and
D. Eisenberg. 2004. Prolinks: a database of protein functional linkages derived from coevolution. Genome Biol. 5:R35.
3. Burland, V., Y. Shao, N. T. Perna, G. Plunkett, H. J. Sofia, and F. R.
Blattner. 1998. The complete DNA sequence and analysis of the large
virulence plasmid of Escherichia coli O157:H7. Nucleic Acids Res. 26:4196–
4204.
4. Camilli, A., and J. J. Mekalanos. 1995. Use of recombinase gene fusions to
identify Vibrio cholerae genes induced during infection. Mol. Microbiol. 18:
671–683.
5. Cao, S. L., A. Progulske-Fox, J. D. Hillman, and M. Handfield. 2004. In vivo
induced antigenic determinants of Actinobacillus actinomycetemcomitans.
FEMS Microbiol. Lett. 237:97–103.
6. Deng, W., J. L. Puente, S. Gruenheid, Y. Li, B. A. Vallance, A. Vazquez, J.
Barba, J. A. Ibarra, P. O’Donnell, P. Metalnikov, K. Ashman, S. Lee, D.
Goode, T. Pawson, and B. B. Finlay. 2004. Dissecting virulence: systematic
and functional analyses of a pathogenicity island. Proc. Natl. Acad. Sci. USA
101:3597–3602.
7. Dozois, C. M., F. Daigle, and R. Curtiss III. 2003. Identification of pathogenspecific and conserved genes expressed in vivo by an avian pathogenic Escherichia coli strain. Proc. Natl. Acad. Sci. USA 100:247–252.
8. Groisman, E. A. 2001. The pleiotropic two-component regulatory system
PhoP-PhoQ. J. Bacteriol. 183:1835–1842.
9. Gruenheid, S., I. Sekirov, N. A. Thomas, W. Deng, P. O’Donnell, D. Goode,
Y. Li, E. A. Frey, N. F. Brown, P. Metalnikov, T. Pawson, K. Ashman, and
B. B. Finlay. 2004. Identification and characterization of NleA, a non-LEEencoded type III translocated virulence factor of enterohaemorrhagic Escherichia coli O157:H7. Mol. Microbiol. 51:1233–1249.
10. Hagiwara, D., M. Sugiura, T. Oshima, H. Mori, H. Aiba, T. Yamashino, and
T. Mizuno. 2003. Genome-wide analyses revealing a signaling network of the
RcsC-YojN-RcsB phosphorelay system in Escherichia coli. J. Bacteriol. 185:
5735–5746.
11. Handfield, M., L. J. Brady, A. Progulske-Fox, and J. D. Hillman. 2000.
IVIAT: a novel method to identify microbial genes expressed specifically
during human infections. Trends Microbiol. 8:336–339.
12. Hang, L., M. John, M. Asaduzzaman, E. A. Bridges, C. Vanderspurt, T. J.
Kirn, R. K. Taylor, J. D. Hillman, A. Progulske-Fox, M. Handfield, E. T.
Ryan, and S. B. Calderwood. 2003. Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection
with Vibrio cholerae. Proc. Natl. Acad. Sci. USA 100:8508–8513.
13. Harkey, C. W., K. D. Everiss, and K. M. Peterson. 1995. Isolation and
characterization of a Vibrio cholerae gene (tagA) that encodes a ToxRregulated lipoprotein. Gene 153:81–84.
14. Hava, D. L., and A. Camilli. 2002. Large-scale identification of serotype 4
Streptococcus pneumoniae virulence factors. Mol. Microbiol. 45:1389–1405.
15. Heithoff, D. M., C. P. Conner, and M. J. Mahan. 1997. Dissecting the biology
of a pathogen during infection. Trends Microbiol. 5:509–513.
16. Heithoff, D. M., C. P. Conner, U. Hentschel, F. Govantes, P. C. Hanna, and
M. J. Mahan. 1999. Coordinate intracellular expression of Salmonella genes
induced during infection. J. Bacteriol. 181:799–807.
17. Hoch, J., and T. Silhavy. 1995. Two-component signal transduction. ASM
Press, Washington, D.C.
18. Hoffman, J. A., J. L. Badger, Y. Zhang, S. H. Huang, and K. S. Kim. 2000.
Escherichia coli K1 aslA contributes to invasion of brain microvascular endothelial cells in vitro and in vivo. Infect. Immun. 68:5062–5067.
19. Ikeda, M., S. Ito, and M. Honda. 2004. Hemolytic uremic syndrome induced
by lipopolysaccharide and Shiga-like toxin. Pediatr. Nephrol. 19:485–489.
20. John, M., T. I. Crean, S. B. Calderwood, and E. T. Ryan. 2000. In vitro and
in vivo analyses of constitutive and in vivo-induced promoters in attenuated
vaccine and vector strains of Vibrio cholerae. Infect. Immun. 68:1171–1175.
21. Kaper, J. B., J. P. Nataro, and H. L. Mobley. 2004. Pathogenic Escherichia
coli. Nat. Rev. Microbiol. 2:123–140.
22. Karpman, D., Z. D. Bekassy, A. C. Sjogren, M. S. Dubois, M. A. Karmali, M.
Mascarenhas, K. G. Jarvis, L. J. Gansheroff, A. D. O’Brien, G. S. Arbus, and
J. B. Kaper. 2002. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections.
Pediatr. Nephrol. 17:201–211.
23. Kim, S. H., W. Jia, R. E. Bishop, and C. Gyles. 2004. An msbB homologue
carried in plasmid pO157 encodes an acyltransferase involved in lipid A
biosynthesis in Escherichia coli O157:H7. Infect. Immun. 72:1174–1180.
24. Kudva, I. T., P. S. Evans, N. T. Perna, T. J. Barrett, G. J. DeCastro, F. M.
Ausubel, F. R. Blattner, and S. B. Calderwood. 2002. Polymorphic amplified

typing sequences provide a novel approach to Escherichia coli O157:H7
strain typing. J. Clin. Microbiol. 40:1152–1159.
Kudva, I. T., R. W. Griffin, M. Murray, M. John, N. T. Perna, T. J. Barrett,
and S. B. Calderwood. 2004. Insertions, deletions, and single-nucleotide
polymorphisms at rare restriction enzyme sites enhance discriminatory
power of polymorphic amplified typing sequences, a novel strain typing
system for Escherichia coli O157:H7. J. Clin. Microbiol. 42:2388–2397.
Kwon, Y. M., and S. C. Ricke. 1998. Induction of acid resistance of Salmonella typhimurium by exposure to short-chain fatty acids. Appl. Environ.
Microbiol. 64:3458–3463.
Lee, A. I., A. Delgado, and R. P. Gunsalus. 1999. Signal-dependent phosphorylation of the membrane-bound NarX two-component sensor-transmitter protein of Escherichia coli: nitrate elicits a superior anion ligand response
compared to nitrite. J. Bacteriol. 181:5309–5316.
Leonhartsberger, S., A. Huber, F. Lottspeich, and A. Bock. 2001. The
hydH/G genes from Escherichia coli code for a zinc and lead responsive
two-component regulatory system. J. Mol. Biol. 307:93–105.
Li, Y., E. Frey, A. M. R. Mackenzie, and B. B. Finlay. 2000. Human response
to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect. Immun. 68:5090–5095.
Lin, R. J., M. Capage, and C. W. Hill. 1984. A repetitive DNA sequence, rhs,
responsible for duplications within the Escherichia coli K-12 chromosome.
J. Mol. Biol. 177:1–18.
Lucas, R. L., C. P. Lostroh, C. C. DiRusso, M. P. Spector, B. L. Wanner, and
C. A. Lee. 2000. Multiple factors independently regulate hilA and invasion
gene expression in Salmonella enterica serovar Typhimurium. J. Bacteriol.
182:1872–1882.
Madrid, C., J. M. Nieto, S. Paytubi, M. Falconi, C. O. Gualerzi, and A.
Juarez. 2002. Temperature- and H-NS-dependent regulation of a plasmidencoded virulence operon expressing Escherichia coli hemolysin. J. Bacteriol.
184:5058–5066.
Mahan, M. J., D. M. Heithoff, R. L. Sinsheimer, and D. A. Low. 2000.
Assessment of bacterial pathogenesis by analysis of gene expression in the
host. Annu. Rev. Genet. 34:139–164.
Mao, Y., M. P. Doyle, and J. Chen. 2001. Insertion mutagenesis of wca
reduces acid and heat tolerance of enterohemorrhagic Escherichia coli O157:
H7. J. Bacteriol. 183:3811–3815.
McKee, M. L., and A. D. O’Brien. 1996. Truncated enterohemorrhagic Escherichia coli (EHEC) O157:H7 intimin (EaeA) fusion proteins promote adherence of EHEC strains to HEp-2 cells. Infect. Immun. 64:2225–2233.
McNally, A., A. J. Roe, S. Simpson, F. M. Thomson-Carter, D. E. E. Hoey, C.
Currie, T. Chakraborty, D. G. E. Smith, and D. L. Gally. 2001. Differences
in levels of secreted locus of enterocyte effacement proteins between human
disease-associated and bovine Escherichia coli O157. Infect. Immun. 69:
5107–5114.
Mei, J., F. Nourbakhsh, C. Ford, and D. Holden. 1997. Identification of
Staphylococcus aureus virulence genes in a murine model of bacteremia using
signature-tagged mutagenesis. Mol. Microbiol. 26:399–407.
Merrell, D. S., D. L. Hava, and A. Camilli. 2002. Identification of novel
factors involved in colonization and acid tolerance of Vibrio cholerae. Mol.
Microbiol. 43:1471–1491.
Miranda, R. L., T. Conway, M. P. Leatham, D. E. Chang, W. E. Norris, J. H.
Allen, S. J. Stevenson, D. C. Laux, and P. S. Cohen. 2004. Glycolytic and
gluconeogenic growth of Escherichia coli O157:H7 (EDL933) and E. coli
K-12 (MG1655) in the mouse intestine. Infect. Immun. 72:1666–1676.
Neidhardt, F. C., R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B.
Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger.
1996. Escherichia coli and Salmonella: molecular and cellular biology. American Society for Microbiology, Washington, D.C.
Paton, A. W., and J. C. Paton. 2002. Reactivity of convalescent-phase hemolytic-uremic syndrome patient sera with the megaplasmid-encoded TagA
protein of Shiga-toxigenic Escherichia coli O157. J. Clin. Microbiol. 40:
1395–1399.
Peekhaus, N., and T. Conway. 1998. What’s for dinner? Entner-Doudoroff
metabolism in Escherichia coli. J. Bacteriol. 180:3495–3502.
Peng, J., J. E. Elias, C. C. Thoreen, L. J. Licklider, and S. P. Gygi. 2003.
Evaluation of multidimensional chromatography coupled with tandem mass
spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast
proteome. J. Proteome Res. 2:43–50.
Perna, N. T., G. Plunkett, V. Burland, B. Mau, J. D. Glasner, D. J. Rose,
G. F. Mayhew, P. S. Evans, J. Gregor, H. A. Kirkpatrick, G. Posfai, J.
Hackett, S. Klink, A. Boutin, Y. Shao, L. Miller, E. J. Grotbeck, N. W. Davis,
A. Lim, E. T. Dimalanta, K. D. Potamousis, J. Apodaca, T. S. Anantharaman, J. Lin, G. Yen, D. C. Schwartz, R. A. Welch, and F. R. Blattner. 2001.
Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature
409:529–533.
Polen, T., D. Rittmann, V. F. Wendisch, and H. Sahm. 2003. DNA microarray analyses of the long-term adaptive response of Escherichia coli to acetate
and propionate. Appl. Environ. Microbiol. 69:1759–1774.
Rabin, R. S., and V. Stewart. 1992. Either of two functionally redundant
sensor proteins, NarX and NarQ, is sufficient for nitrate regulation in Escherichia coli K-12. Proc. Natl. Acad. Sci. USA 89:8419–8423.

VOL. 73, 2005

Editor: A. D. O’Brien

2679

54. Torres, A. G., and J. B. Kaper. 2003. Multiple elements controlling adherence of enterohemorrhagic Escherichia coli O157:H7 to HeLa cells. Infect.
Immun. 71:4985–4995.
55. von Kruger, W. M. A., S. Humphreys, and J. M. Ketley. 1999. A role for the
PhoBR regulatory system homologue in the Vibrio cholerae phosphatelimitation response and intestinal colonization. Microbiology 145:2463–
2475.
56. Wagner, P. L., and M. K. Waldor. 2002. Bacteriophage control of bacterial
virulence. Infect. Immun. 70:3985–3993.
57. Wang, L., and P. R. Reeves. 1998. Organization of Escherichia coli O157 O
antigen gene cluster and identification of its specific genes. Infect. Immun.
66:3545–3551.
58. Wosten, M. M., L. F. Kox, S. Chamnongpol, F. C. Soncini, and E. A.
Groisman. 2000. A signal transduction system that responds to extracellular
iron. Cell 103:113–125.
59. Xu, Q., M. Dziejman, and J. J. Mekalanos. 2003. Determination of the
transcriptome of Vibrio cholerae during intraintestinal growth and midexponential phase in vitro. Proc. Natl. Acad. Sci. USA 100:1286–1291.
60. Yim, H. H., and M. Villarejo. 1992. osmY, a new hyperosmotically inducible
gene, encodes a periplasmic protein in Escherichia coli. J. Bacteriol. 174:
3637–3644.
61. Yokoseki, T., T. Iino, and K. Kutsukake. 1996. Negative regulation by fliD,
fliS, and fliT of the export of the flagellum-specific anti-sigma factor, FlgM,
in Salmonella typhimurium. J. Bacteriol. 178:899–901.

Downloaded from http://iai.asm.org/ on February 8, 2014 by Washington University in St. Louis

47. Ritchie, J. M., P. L. Wagner, D. W. K. Acheson, and M. K. Waldor. 2003.
Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.
Appl. Environ. Microbiol. 69:1059–1066.
48. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory
manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y.
49. Sharma, V. K., and R. L. Zuerner. 2004. Role of hha and ler in transcriptional regulation of the esp operon of enterohemorrhagic Escherichia coli
O157:H7. J. Bacteriol. 186:7290–7301.
50. Sinclair, J. F., and A. D. O’Brien. 2002. Cell surface-localized nucleolin is a
eukaryotic receptor for the adhesin intimin-␥ of enterohemorrhagic Escherichia coli O157:H7. J. Biol. Chem. 277:2876–2885.
51. Soncini, F. C., and E. A. Groisman. 1996. Two-component regulatory systems can interact to process multiple environmental signals. J. Bacteriol. 178:
6796–6801.
52. Sperandio, V., A. G. Torres, and J. B. Kaper. 2002. Quorum sensing Escherichia coli regulators B and C (QseBC): a novel two-component regulatory
system involved in the regulation of flagella and motility by quorum sensing
in E. coli. Mol. Microbiol. 43:809–821.
53. Sperandio, V., C. C. Li, and J. B. Kaper. 2002. Quorum-sensing Escherichia
coli regulator A: a regulator of the LysR family involved in the regulation of
the locus of enterocyte effacement pathogenicity island in enterohemorrhagic E. coli. Infect. Immun. 70:3085–3093.

O157 GENES INDUCED DURING HUMAN INFECTION

